KRS Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

KRS Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-55	Closed	–	–	332
2021 Q4	$0	Buy	+55	New	+$772	﹤0.01%	398

Other funds holding TAK

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

KRS Capital Management's TAK Position: Q1 2022 in Review

KRS Capital Management sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 55 shares.

KRS Capital Management first reported a position in TAK in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 287 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

KRS Capital Management reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
KRS Capital Management sold 55 Takeda Pharmaceutical shares in Q1 2022.
KRS Capital Management first reported a position in Takeda Pharmaceutical in Q4 2021 and held it in 1 quarter.
KRS Capital Management's Takeda Pharmaceutical position peaked at $0 in Q4 2021.
287 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.